The FDA approved the combination of Padcev and Keytruda as a treatment for muscle-invasive bladder cancer given both before and after surgery. The clearance covers patients whether or not they can tolerate cisplatin, the platinum chemotherapy that has anchored treatment for decades. It is the first platinum-free regimen approved for this stage of the disease.
The data behind it is strong. In the Phase 3 trial, the pairing cut the risk of tumor recurrence, progression, or death by close to half against the old standard of care. It also lowered the risk of death by about a third in patients who were eligible for chemotherapy. Those are the kinds of numbers that change how doctors treat a cancer, not just add a line to a label.
Why It Matters for Merck
Keytruda is the most important drug in medicine by sales. It brings Merck roughly $30 billion a year, close to half of the company's total revenue of about $66 billion. That concentration is also Merck's biggest risk, because Keytruda's main patents begin to expire near the end of this decade.
Every new approval that moves Keytruda into earlier, curable stages of cancer does two things. It grows the franchise now, and it builds the case for the follow-on version Merck is developing to defend the revenue later. A bladder cancer win in the surgical setting is exactly the kind of expansion that stretches the runway. Merck pays a dividend yielding about 2.7% and has kept raising it, and the durability of that payout rests on how well the company replaces Keytruda over the next several years.
Why It Matters for Pfizer
Padcev belongs to Pfizer, which gained the drug through its Seagen acquisition and shares it with partner Astellas. Pfizer needs wins like this. The company is still working through the drop-off from its COVID products, and its stock trades around 19 times earnings with a dividend yielding close to 7%, one of the highest in large-cap health care.
That yield is the market's way of saying it doubts Pfizer can grow. A drug like Padcev pushing into a larger, earlier-stage patient population is part of the answer. Bladder cancer is one of the more common cancers, and moving a therapy from late-stage rescue to standard pre-surgery care expands the number of patients who take it. For a company leaning on its pipeline to cover a near $63 billion revenue base, each approval that widens a franchise helps support that payout.
What to Watch From Here
The next question is uptake. An approval sets the ceiling, but doctors and insurers decide how fast a chemo-free regimen replaces the old platinum standard. Watch how quickly it shows up in treatment guidelines and in Merck's and Pfizer's oncology sales in the quarters ahead. For both companies, the story is the same: single drugs carrying too much weight, and every new use that spreads the load.
